Atovaquone
Atovaquone.JPG

Atovaquone

CLINICAL USE

Treatment of PCP if intolerant to co-trimoxazole

DOSE IN NORMAL RENAL FUNCTION

750 mg twice daily for 21 days

PHARMACOKINETICS

  • Molecular weight                           :366.8
  • %Protein binding                           :99.9
  • %Excreted unchanged in urine     : <1
  • Volume of distribution (L/kg)       :0.62 ± 0.19
  • half-life – normal/ESRD (hrs)      :2–3 days/no data

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antibacterials: rifampicin, rifabutin and tetracyclines reduce levels by 50%
  • Metoclopramide: significant reduction in plasma atovaquone levels

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

  • Administer with food. The presence of food, particularly high fat food, increases bioavailability 2 or 3-fold.
  • The most commonly reported abnormalities in laboratory parameters are increased liver function tests and amylase levels, and hyponatraemia



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs